Base de dados : LILACS
Pesquisa : A11.642 [Categoria DeCS]
Referências encontradas : 67 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 7 ir para página                  

  1 / 67 LILACS  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Texto completo
Id: biblio-915185
Autor: Corassa, Marcelo; Guimarães, Andrea Paiva Gadelha; Sanches, Solange Moraes; Fanelli, Marcello Ferretti; Rocha, Bruna Maria M; Costa, Alexandre Andre Balieiro A. da; Alves, Vanessa; Baiocchi, Glauco; Chinen, Ludmilla T. Domingos.
Título: Circulating tumor cells as a new and additional approach to follow-up patients with serous low-grade ovarian adenocarcinoma: a case report and review of the literature
Fonte: Appl. cancer res;37:1-6, 2017. ilus.
Idioma: en.
Resumo: Background: Current methods for follow-up of Ovarian Cancer (OC) are widespread, especially with CA125, which, however, is not a perfect biomarker and thus further investigation for new methods of evaluation are warranted. The feasibility of Circulating Tumor Cells (CTCs) in advanced OC was investigated in this case report. Case presentation: A 19-year-old woman with advanced low-grade serous papillary adenocarcinoma and relapsed disease did not have a CA125 correspondent with disease relapse. CTCs were evaluated, compared with CA125 and with image exams. Relapses were not correspondent to elevations of CA125. CTCs demonstrated usefulness, being proportional to major disease relapse, especially in the peritoneum. CTCs may be used as a complementary diagnosis tool when marginal/small increases in CA-125 levels are observed. Conclusions: In OC, CTCs can be an important tool to predict recurrence, response to treatment and improve the quality of decision-making, in order to offer the best treatment to a determined group of patients (AU)
Descritores: Neoplasias Ovarianas/genética
Adenocarcinoma
Biomarcadores Tumorais
Protocolos Clínicos
Células Neoplásicas Circulantes
Limites: Humanos
Feminino
Adulto
Tipo de Publ: Relatos de Casos
Responsável: BR30.1 - Biblioteca


  2 / 67 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Texto completo
Id: biblio-911639
Autor: GE4GAC network members.
Título: Genomics and epidemiology for gastric adenocarcinomas
Fonte: Appl. cancer res;37:1-0, 2017. tab.
Idioma: en.
Resumo: Whereas the pathological aspects of Gastric Adenocarcinomas (GACs) have been well defined, the actual knowledge of its genesis and evolution remains to be translated to better diagnosis and to more effective therapeutics. As a consequence, the current treatment modalities are not yet able to modify the natural history of the disease, which still presents high mortality-rates worldwide. In this review we highlight the current status of relevant epidemiologic, therapeutic and genomics aspects of GACs and point to some of the current knowledge gaps that, if fully addressed, could contribute to a more effective treatment and better management of the patients that suffer from this often-lethal disease (AU)
Descritores: Prognóstico
Neoplasias Gástricas/epidemiologia
Epidemiologia
Estudo Multicêntrico
Terapia Neoadjuvante
Genômica
Microbiota
Vesículas Extracelulares
Sequenciamento Completo do Exoma
Células Neoplásicas Circulantes
Limites: Humanos
Tipo de Publ: Revisão
Responsável: BR30.1 - Biblioteca


  3 / 67 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Texto completo
Id: biblio-910540
Autor: Miola, TM; Conceição, ELS; Souza, JO; Barbosa, PNV; Coimbra, FJF; Bitencourt, AGV.
Título: CT assessment of nutritional status and lean body mass in gastric and esophageal cancer
Fonte: Appl. cancer res;38:5-12, jan. 30, 2018. tab, Ilus.
Idioma: en.
Resumo: Background: Malnutrition is common in patients with gastric and esophageal tumors, and is predominantly associated with loss of lean body mass. Adequate assessment of preoperative nutritional status is essential for prognostication and multidisciplinary treatment planning. The aim of this study was to ascertain whether anthropometric nutritional assessment correlates with computed tomography (CT) measured lean body mass in patients with gastric and/or esophageal cancer. Methods: This was a retrospective analysis of abdominal CT images and anthropometric nutritional assessments. The anthropometric parameters of interest were weight, height, body mass index, mid-upper arm circumference, triceps skinfold thickness, mid-arm muscle circumference, and nutritional diagnosis. The lean muscle mass area was calculated from axial-view CT images of the abdomen at the level of L3 and corrected by height for calculation of the lean mass index. Values below 55.4 cm2 /m2 for males and 38.9 cm2 /m2 for females were defined as low lean body mass. Results: The sample included 70 patients, of whom 67.1% were men. The mean lean body mass index assessed by computed tomography was 47.8 cm2 /m2 (range, 29.2­78.6cm2 /m2), with 54.3% of patients being classified as having low lean body mass. When classified by mid-arm muscle circumference, 74.2% of patients classified as undernourished had low lean body mass on CT, compared to 40.0% of patients classified as well-nourished (sensitivity 62.2%, specificity 72.4%, accuracy 66.7%). Conclusions: A substantial portion of patients with gastric and/or esophageal cancer exhibited low lean body mass on computed tomography. Anthropometric evaluation has limited capacity to identify these patients. Among the tested anthropometric parameter, mid-arm muscle circumference showed the best agreement with CT-measured lean body mass
Descritores: Neoplasias Pulmonares
Células Neoplásicas Circulantes
Metástase Neoplásica
Limites: Humanos
Masculino
Feminino
Pessoa de Meia-Idade
Responsável: BR30.1 - Biblioteca


  4 / 67 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Texto completo
Id: biblio-910469
Autor: Abraham, J; Singh, S; Joshi, S.
Título: Liquid biopsy: emergence of a new era in personalized cancer care
Fonte: Appl. cancer res;38:1-17, jan. 30, 2018. tab, ilus.
Idioma: en.
Resumo: The most successful treatment for cancer involves identifying druggable, biological markers for targeted therapy. In the clinical setting, surgical removal of tumors is the only procedure for identifying such targetable molecules. Shed from tumor cells, these markers are also present in circulating blood, albeit in very negligible amounts. Liquid biopsy is a procedure performed on a blood sample to look for such circulating cancer markers cells or pieces of nucleic acid from the tumor. The procedure shows promise in revolutionizing personalized cancer treatments. Here we briefly review the technique, characterization, and its utilization in clinics
Descritores: Biomarcadores
Terapia de Alvo Molecular
Ácidos Nucleicos Livres
Biópsia Líquida
Células Neoplásicas Circulantes
Limites: Humanos
Tipo de Publ: Revisão
Responsável: BR30.1 - Biblioteca


  5 / 67 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Texto completo
Id: biblio-910438
Autor: Diaz, MTM; Abdallah, EA; Tariki, MS; Braun, AC; Dettino, ALA; Nicolau, UR; Alves, VS; Chnen, LTD.
Título: Circulating tumor cells as marker of poor prognosis in metastatic lung cancer: a pilot study
Fonte: Appl. cancer res;38:1-7, jan. 30, 2018. tab, ilus.
Idioma: en.
Resumo: Background: Circulating tumor cells (CTCs) play an important role in progression and metastasis, particularly in form of cluster, which is called circulating tumor microemboli (CTM), and can be found in the peripheral blood of cancer patients. The aim of this study was to evaluate the presence of CTCs and CTM, and its influence on tumor progression in lung cancer patients. Methods: CTCs were isolated by Isolation by Size of Epithelial Tumor cells (ISET®) Technology. The samples of metastatic lung cancer patients were collected before the beginning of systemic chemotherapy. CTCs and CTM were identified according to their morphological features. Results: Fifteen patients were analyzed. Patients who had CTM in blood previously the beginning of systemic therapy had poor progression-free survival (PFS) compared to those with absence of CTM, although without statistical significance (median PFS 3.1 months × 6.7 months, p = 0.29). Moreover, patients without any prior treatment had less than 3 CTCs/mL compared to patients previously exposed to chemotherapy, who had 3 CTCs/mL or more (p = 0.31). Additionally, these patients, with prior treatment, showed poor PFS, compared to chemo-naive patients, although without statistical significance (mean PFS: 4.6 months × 7.3 months, p = 0.47). Conclusions: We identified, even in a limited number of samples, that an elevated baseline levels of CTCs and the presence of CTM were associated with poor prognosis in patients with metastatic lung cancer. In addition, we showed that an increase of CTCs counts could indicate a pre-existing resistance. However, further studies with a large cohort are needed to support this information
Descritores: Projetos Piloto
Neoplasias Pulmonares
Células Neoplásicas Circulantes
Metástase Neoplásica
Limites: Humanos
Responsável: BR30.1 - Biblioteca


  6 / 67 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Id: lil-706012
Autor: Chinen, Ludmilla Thomé Domingos; Rocha, Bruna Maria Malagoli; Fanelli, Marcello Ferretti.
Título: Circulating tumor cells: basic concepts and some clinical applications
Fonte: Appl. cancer res;32(4):142-152, 2012. tab.
Idioma: en.
Resumo: The spread of cancer requires the presence of circulating tumor cells (CTCs), which are rare cells surrounded by billions of normal hematopoietic cells in the bloodstream. It is believed thatCTCs tend to metastasize to certain organs, thus, their presence may determine invasive tumor behavior. Generally, these cells are undetectable by conventional histopathological analysisand imaging exams with high resolution. Therefore, more sensitive immunohistochemical and molecular assays have been developed that have allowed the specific detection of metastatic tumor cells in regional lymph nodes, peripheral blood and bone marrow. This article reviews theliterature regarding CTCs and tumors of the breast, colorectal, pancreas and lung as it pertains to forms of detection and clinicopathological correlations, in addition to future outlooks
Descritores: Células Neoplásicas Circulantes
Imuno-Histoquímica
Literatura de Revisão como Assunto
Limites: Humanos
Tipo de Publ: Revisão
Responsável: BR30.1 - Biblioteca


  7 / 67 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Id: lil-734448
Autor: Cáceres, Hernán J.
Título: ¿La Biología del tumor es la clave? / Is the biology of the tumor the key?
Fonte: Rev. am. med. respir;14(3):353-353, set. 2014.
Idioma: es.
Resumo: ¿Por qué algunos pacientes desarrollan Carcinomatosis Linfática pulmonar (CLP) o Embolismo Pulmonar Tumoral (EPT) de manera precoz? ¿Por qué otros pacientes lo desarrollan tardíamente o no lo desarrollan? ¿Es tal vez la Biología del tumor la piedra angular para su comprensión?
Descritores: Carcinoma
Embolia
Células Neoplásicas Circulantes
Responsável: AR423.1 - Biblioteca


  8 / 67 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Texto completo
Id: biblio-951907
Autor: Oliveira, Isadora Bernardo David de; Hirata, Rosario Dominguez Crespo.
Título: Circulating cell-free DNA as a biomarker in the diagnosis and prognosis of colorectal cancer
Fonte: Braz. J. Pharm. Sci. (Online);54(1):e17368, 2018. tab, graf.
Idioma: en.
Resumo: Abstract Colorectal cancer (CRC) is a disease without evident clinical symptoms in early stages, leading to late diagnosis and disease management. Current diagnostic and prognostic tools require invasive procedures and circulating molecular biomarkers fail to have optimal sensitivity and specificity. Circulating biomarkers with high clinical performance may be valuable for early diagnosis and prognosis of CRC. The purpose of this review was to investigate the application of circulating cell-free DNA (ccfDNA) in CRC diagnosis and prognosis and the analytical methods used in blood samples in articles published between 2005 and 2016. Based on specific inclusion and exclusion criteria, 26 articles were selected. Most studies used ccfDNA quantification as the molecular biomarker. The analytical method was mainly based on the quantitative polymerase chain reaction (qPCR). Biomarkers based on aberrantly methylated genes (n=6) and ccfDNA integrity/fragmentation (n=2) were also used for the CRC diagnosis. The CRC prognosis used the detection of oncogene mutations, such as KRAS and BRAF, in ccfDNA. Significant differences were found in variables among the studies revealing potential bias. ccfDNA quantification as a diagnostic biomarker for CRC has promising results but it lacks clinical specificity since other diseases present a similar increase in ccfDNA content. However, increasing research in the epigenomic field can lead the way to a clinically specific biomarker for the CRC early diagnosis. As for the analytical method, qPCR and derivatives seem to be a perfectly valid technique. The use of ccfDNA quantification in CRC prognosis seems promising. The attempt to use the ccfDNA quantification in clinical practice may reside in the prognosis using a qPCR technique.
Descritores: Prognóstico
Neoplasias Colorretais/diagnóstico
Ácidos Nucleicos Livres/efeitos adversos
-Biomarcadores
Diagnóstico Precoce
Células Neoplásicas Circulantes
Tipo de Publ: Revisão
Responsável: BR40.1 - DBD - Divisão de Biblioteca e Documentacão do Conjunto das Químicas


  9 / 67 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: lil-741102
Autor: Machado, L H A; Palumbo, M I P; Zahn, F S; Amorim, R L; Farias, M R; Werner, J; Torres Neto, R; Rodrigues, J C; Oliveira, F C.
Título: Comparative study of histopathology and immunohistochemistry of indefinite round cell cutaneous tumors and characterization of canine lymphoma / Estudo comparativo de histopatologia e imuno-histoquímica de tumores indefinidos de células redondas e caracterização de linfoma canino
Fonte: Arq. bras. med. vet. zootec;67(1):32-36, 2/2015. tab.
Idioma: en.
Resumo: With the purpose of shedding light on some doubts in veterinary oncology, the present article intends to compare the results of histopathological and immunohistochemical examinations of unspecific round cell neoplasia, to realize immunophenotyping of canine lymphoma cases, to establish the T or B origin of neoplastic cells, and to determine the degree of proliferation and apoptosis of lymphomas by immunohistochemistry. Of 11 animals presenting immunohistochemical diagnosis of lymphoma, five had been diagnosed as Lymphoma by HE staining of histopathological slides and six had been classified as unspecific round cell neoplasia. All cases submitted to immunohistochemical examination were T-cell lymphomas. There was a positive correlation between cell proliferation and apoptosis. The comparison among histopathological and immunohistochemical results obtained in the cases examined in the present study suggested that immunohistochemistry is essential for the differentiation of round cell neoplasia.

Com o objetivo de sanar algumas dúvidas na área da oncologia veterinária, o presente artigo pretende comparar os resultados dos exames histopatológicos e imuno-histoquímicos de neoplasias de células redondas inespecíficas, realizar imunofenotipagem dos casos de linfoma canino e determinar o grau de proliferação e apoptose de linfomas. Dos 11 animais que apresentaram diagnóstico imuno-histoquímico de linfoma, cinco foram diagnosticados como linfoma por coloração HE das lâminas histopatológicas e seis foram classificados como neoplasia de células redondas inespecíficas. Todos os casos submetidos ao exame imuno-histoquímico foram de linfomas de células-T. Houve uma correlação positiva entre a proliferação celular e apoptose. A comparação entre os resultados histopatológicos e imuno-histoquímicos obtidos nos casos analisados sugeriu que a imuno-histoquímica é essencial para a diferenciação das neoplasias de células redondas.
Descritores: Linfoma/classificação
Células Neoplásicas Circulantes/imunologia
Células Neoplásicas Circulantes/patologia
Limites: Animais
Cães
Responsável: BR1.1 - BIREME


  10 / 67 LILACS  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
Texto completo
Id: biblio-847321
Autor: Carpinetti-Oliveira, Paola de Avelar.
Título: Identificação e estudo de biomarcadores personalizados para avaliação e seguimento de pacientes com câncer de reto tratados com quimioradioterapia neoadjuvante / Identification and study of personalized biomarkers for assessment and follow-up of patients with rectal cancer treated with neoadjuvant chemoradiotherapy.
Fonte: São Paulo; s.n; 2015. 133 p. tab, graf, ilus.
Idioma: pt.
Tese: Apresentada a Universidade de São Paulo. Instituto de Química para obtenção do grau de Doutor.
Resumo: O tratamento padrão para pacientes com câncer de reto localmente avançado consiste no uso de quimioradioterapia neoadjuvante (QRTn), seguida por cirurgia. Uma fração significativa dos pacientes responde completamente ao tratamento e no momento da reavaliação não apresenta evidência clínica nem radiológica de doença. Uma abordagem alternativa, Watch and Wait, propõe não operar imediatamente esses pacientes e submetê-los a um protocolo de observação frequente, a fim de evitar as morbidades associadas à cirurgia. No entanto, a avaliação da resposta ao tratamento ainda é um desafio, devido à subjetividade da avaliação clínica e a ausência de exames radiológicos suficientemente sensíveis e específicos para garantir a ausência de células tumorais residuais ou capazes de detectar a recorrência precoce da doença. DNA circulante contendo alterações genéticas específicas do tumor (ctDNA) pode ser encontrado na fração livre de células do sangue e tem sido utilizado para monitorar a dinâmica tumoral em tumores sólidos. Avanços recentes das tecnologias de sequenciamento permitem a identificação eficiente e rápida e a um custo relativamente baixo de alterações genéticas em tumores individuais, superando o problema imposto pela ausência de alterações genéticas recorrentes nesses tumores. Essas alterações podem ser utilizadas como biomarcadores personalizados para monitorar a resposta ao tratamento, detectar doença residual e a recidiva precoce do tumor. O objetivo deste trabalho foi identificar e estudar biomarcadores personalizados em pacientes com câncer de reto localmente avançado tratados com QRTn e avaliar a capacidade desses biomarcadores para monitorar a dinâmica tumoral, e auxiliar na definição da conduta cirúrgica e na detecção da recidiva precoce da doença. Biópsias de seis pacientes com adenocarcinoma de reto distal (cT2- 3N0-1M0), foram coletadas prospectivamente pré-tratamento. O DNA genômico extraído a partir das biópsias foi usado para construir bibliotecas tipo mate-pair para o sequenciamento do genoma completo, utilizando a plataforma SOLiD. Rearranjos inter e intracromossômicos foram identificados utilizando programas computacionais desenvolvidos pelo nosso grupo de pesquisa e em seguida foram validados utilizando PCR e sequenciamento Sanger. Foram validadas, pelo menos, três variações estruturais para cada paciente. Amostras de plasma foram coletadas no momento do diagnóstico, depois da QRTn e durante o seguimento. DNA circulante total foi extraído a partir das amostras de plasma e ensaios personalizados foram desenvolvidos para monitorar a presença de variações estruturais através de PCR Digital. ctDNA foi detectado em todas amostras de plasma pré-tratamento de pacientes com tumores T3. A detecção desses biomarcadores apresentou boa correlação com a resposta ao tratamento, no entanto, esta abordagem não foi sensível o suficiente para detectar doença residual. Para dois pacientes que desenvolveram doença metastática foi verificado um aumento nos níveis de ctDNA com pelo menos 36 semanas antes do diagnóstico clínico de doença metastática, sendo possível correlacionar os níveis de ctDNA detectados em coletas subsequentes com a resposta ao tratamento sistêmico de segunda linha. Este estudo, embora de caráter exploratório, gerou dados relevantes e suficientes para justificar a realização de estudos adicionais para avaliar a aplicação dos biomarcadores personalizados na definição da conduta cirúrgica e no acompanhamento de pacientes com câncer de reto tratados com QRTn

The standard treatment for patients with locally advanced rectal cancer comprises in neoadjuvant chemo radiotherapy (nCRT), followed by surgery. A significant fraction of these patients show complete response to the treatment and at the time of reassessment, there are no clinical and nor radiological evidence of residual tumor. An alternative approach, Watch and Wait, proposes not to immediately operate these patients, but to submit them to a protocol of frequent observation in order to avoid the morbidities associated with radical surgery. However, assessment of treatment response remains a significant challenge due to the subjectivity of the clinical examination and to the lack of sufficiently sensitive tools to ensure the absence of tumor cells or to detect early disease recurrence. Circulating DNA carrying tumor-specific genetic alterations (circulating tumor DNA - ctDNA) can be found in the cell-free fraction of the blood and has been successfully used to monitor the tumor dynamics in solid tumors. Recent advances in sequencing technologies have enabled the rapid and cost effective identification of genetic alterations in individual tumors, overcoming the problem imposed by the absence of recurrent genetic alterations in these tumors. These alterations can be used as personalized biomarkers to monitor treatment response, detect residual disease and early tumor recurrence. The purpose of this work was to identify and validate the use of personalized biomarkers for patients with locally advanced rectal cancer treated with nCRT and to evaluate the ability of these biomarkers to monitor the tumor dynamics, to define surgical approach and to detect early recurrence of the disease. Pre-treatment biopsies from 6 patients with cT2-3N0-1M0 distal rectal adenocarcinoma were prospectively collected. Genomic DNA extracted from the biopsies was used to construct mate-pair libraries for whole genome sequencing using SOLiD platform. Inter and intrachromosomal rearrangements were identified using an in-house bioinformatics pipeline and validated using PCR amplification and Sanger sequencing. At least three structural variations were validated for each patient. Plasma samples were collect at diagnosis, after nCRT and follow-up. Circulating DNA was obtained from the plasma samples and personalized assays were designed to monitor the presence of structural variations using Droplet Digital PCR. ctDNA was detected in all pre-treatment plasma samples for patients with T3 tumors. The detection of these biomarkers showed a good correlation with the treatment response, nonetheless, the approach was not sensitive enough to detect residual disease. In two patients who developed metastatic disease, an increase in ctDNA levels was observed at least 36 weeks before clinical detection of metastatic disease, and it was possible to correlate the level of ctDNA in subsequent plasma samples with response to the second-line treatment. This study, although exploratory, generated relevant and sufficient data to support additional studies to evaluate the use of personalized biomarkers in the surgical management and follow-up of rectal cancer patients treated with nCRT
Descritores: Biomarcadores Tumorais/análise
DNA/genética
Terapia Neoadjuvante/classificação
Neoplasias Retais/patologia
-Biblioteca Gênica
Células Neoplásicas Circulantes/metabolismo
Reação em Cadeia da Polimerase/métodos
Limites: Masculino
Feminino
Tipo de Publ: Estudo de Avaliação
Responsável: BR40.1 - DBD - Divisão de Biblioteca e Documentacão do Conjunto das Químicas
BR40.1; T 574.88, C298i. 30100025446-Q



página 1 de 7 ir para página                  
   


Refinar a pesquisa
  Base de dados : Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde